muraglitazar has been researched along with oleic acid in 1 studies
| Studies (muraglitazar) | Trials (muraglitazar) | Recent Studies (post-2010) (muraglitazar) | Studies (oleic acid) | Trials (oleic acid) | Recent Studies (post-2010) (oleic acid) |
|---|---|---|---|---|---|
| 85 | 10 | 25 | 8,768 | 248 | 3,051 |
| Protein | Taxonomy | muraglitazar (IC50) | oleic acid (IC50) |
|---|---|---|---|
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | 6.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anthérieu, S; Claude, N; de la Moureyre-Spire, C; Guillouzo, A; Rogue, A; Umbdenstock, T; Vluggens, A; Weaver, RJ | 1 |
1 other study(ies) available for muraglitazar and oleic acid
| Article | Year |
|---|---|
PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
Topics: Cell Line; Constitutive Androstane Receptor; Drug Evaluation, Preclinical; Fatty Acids, Nonesterified; Fatty Liver; Gene Expression Regulation; Glycine; Humans; Lipid Metabolism; Lipogenesis; Lipotropic Agents; Liver; Liver X Receptors; Non-alcoholic Fatty Liver Disease; Oleic Acid; Orphan Nuclear Receptors; Oxazoles; Oxidation-Reduction; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Triglycerides | 2014 |